Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update

Rhea-AI Summary

Allogene Therapeutics (Nasdaq: ALLO) will report its second quarter 2026 financial results and provide a business update on August 12, 2026, after the market close. The company will host a live audio webcast and conference call at 2:00 p.m. PT / 5:00 p.m. ET.

The listen-only webcast will be accessible via the Investors > News and Events section of www.allogene.com, with a replay available for about 30 days. Investors who wish to ask questions on the call must register via the provided link to receive a personal PIN for access.

Market Context

The prior earnings-date record contained moves of +6.45% and -4.68%, so the platform history was mix...

Analysis

The prior earnings-date record contained moves of +6.45% and -4.68%, so the platform history was mixed rather than directional. Moderate short positioning was the main sourced risk to monitor.

Key Figures

Reporting date: August 12, 2026 Conference call time: 2:00 p.m. PT / 5:00 p.m. ET Replay availability: approximately 30 days

3 metrics

Reporting date August 12, 2026 Second quarter 2026 financial results and business update

Conference call time 2:00 p.m. PT / 5:00 p.m. ET Following the announcement after market close

Replay availability approximately 30 days Company website webcast replay

Previous Earnings date Reports

2 past events · Latest: May 06 (Neutral)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
May 06	Q1 earnings date	Neutral	+6.5%	Prior Q1 results date announcement preceded a 6.45% 24-hour move.
Mar 02	Q4 earnings date	Neutral	-4.7%	Prior Q4 and full-year results date announcement preceded a -4.68% 24-hour move.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior earnings-date announcements produced mixed reactions, with one positive move and one negative move.

Key Terms

allogeneic CAR T, chimeric antigen receptor T cell

2 terms

allogeneic CAR T medical

"pioneering the development of allogeneic CAR T (AlloCAR T) products"

Allogeneic CAR T is a type of cancer immunotherapy made from immune cells collected from a healthy donor, genetically reprogrammed to recognize and kill cancer cells, and stored like an off‑the‑shelf medicine. For investors it matters because donor-based products can be manufactured at scale and delivered faster and cheaper than patient-specific (custom) therapies, but they also carry different safety and regulatory risks that affect commercial potential and valuation.

chimeric antigen receptor T cell medical

"allogeneic chimeric antigen receptor T cell (AlloCAR T) products"

Chimeric antigen receptor T cell (CAR T cell) is an immune cell that has been taken from a person, genetically modified in a lab to carry a synthetic receptor that recognizes specific markers on disease cells, then returned to the body to seek and destroy those targets. Think of it as giving a patient's T cells a GPS and new weapon to find diseased cells. It matters to investors because CAR T therapies can transform treatment markets, drive clinical and regulatory milestones, and require specialized manufacturing and pricing models that affect company value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Conference Call and Webcast Scheduled for August 12, 2026 at 2:00 p.m. PT/5:00 p.m. ET
  

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will report second quarter 2026 financial results and provide a business update on August 12, 2026, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET.

Listen-Only Webcast
The listen-only webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. A replay will be available on the Company's website for approximately 30 days.

Conference Call Registration
If you would like the option to ask a question on the conference call, please use this link to register. Upon registering for the conference call, you will receive a personal PIN to access the call.

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by cell therapy veterans applying proven CAR T experience, Allogene is developing a pipeline of off-the-shelf CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.

Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factors” heading in its Form 10-Q filed for the quarter ended March 31, 2026. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com

FAQ

When will Allogene Therapeutics (ALLO) report its Q2 2026 financial results?

Allogene Therapeutics will report its second quarter 2026 financial results on August 12, 2026, after the market close. According to Allogene Therapeutics, the release will be accompanied by a business update and a live webcast and conference call.

What time is Allogene Therapeutics' Q2 2026 earnings conference call and webcast for ALLO shareholders?

The Q2 2026 conference call and live audio webcast are scheduled for 2:00 p.m. PT / 5:00 p.m. ET on August 12, 2026. According to Allogene Therapeutics, the event will follow the release of quarterly financial results and a business update.

How can investors access the Allogene Therapeutics (ALLO) Q2 2026 earnings webcast?

Investors can access the listen-only webcast on www.allogene.com under the Investors tab in the News and Events section. According to Allogene Therapeutics, a replay of the webcast will remain available on the website for approximately 30 days after the event.

How do I register to ask questions on the Allogene Therapeutics (ALLO) Q2 2026 earnings call?

To ask questions, investors must use the company’s conference call registration link before the event. According to Allogene Therapeutics, registered participants receive a personal PIN that grants access to the Q2 2026 conference call question-and-answer session.

What does Allogene Therapeutics do as a clinical-stage company for ALLO investors?

Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease. According to Allogene Therapeutics, it is building an off-the-shelf CAR T pipeline aimed at scalable, on-demand cell therapy for more patients.

Will a replay of Allogene Therapeutics' Q2 2026 earnings webcast for ALLO be available?

Yes, a replay of the Q2 2026 webcast will be available on Allogene’s website for about 30 days. According to Allogene Therapeutics, investors can find the replay under the Investors section, providing extended access to the financial update and business commentary.